TABLE 5.
Protective capacity of pooled sera measured in the infant rat passive protection assaya
| Study | Group | Mean log10 CFU/100 μl blood (SD) | P value for difference compared to positive reference (Hib coadministered) |
|---|---|---|---|
| United States | |||
| Postprimary | Control | 4.27 (0.52) | <0.05 |
| DTPa + HBV + OPV + Hib* | <0.85 (0.00) | NS | |
| DTPa-HBV-IPV/Hib | 2.55 (1.65) | NS | |
| Postbooster | Control | 4.37 (0.90) | <0.01 |
| DTPa + Hib* | 1.09 (0.64) | NS | |
| DTPa/Hib | <0.85 (0.00) | NS | |
| Germany A | |||
| Postprimary | Control | 4.89 (0.29) | <0.01 |
| DTPa + Hib | 2.82 (0.73) | NS | |
| DTPa/Hib | 2.07 (1.72) | NS | |
| Postbooster | Control | 4.95 (0.95) | <0.01 |
| DTPa + Hib | <0.85 (0.00) | NS | |
| DTPa/Hib | <0.85 (0.00) | NS | |
| Germany B | |||
| Postprimary | Control | 5.43 (0.53) | <0.01 |
| DTPa-HBV + Hib | 1.48 (0.71) | NS | |
| DTPa-HBV/Hib | 2.43 (2.21) | NS | |
| Postbooster | Control | 5.43 (0.53) | <0.01 |
| dtpa-HBV + PRP | <0.85 (0.00) | NS | |
| dtpa-HBV/PRP | <0.85 (0.00) | NS |
a
Not evaluated in the Myanmar study. NS, no statistically significant difference; dtpa, experimental DTPa vaccine with reduced antigen content; OPV, oral poliovirus vaccine. *, OmniHIB.